Search Result

Results for "

dihydroorotate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dihydroorotate Dehydrogenase (51) Apoptosis (1) Autophagy (3) Bacterial (2) Dengue virus (1) DNA/RNA Synthesis (30) Endogenous Metabolite (6) Flavivirus (1) Fungal (1) FXR (2) Influenza Virus (3) Interleukin Related (2) Lactate Dehydrogenase (2) MDM-2/p53 (3) Nucleoside Antimetabolite/Analog (4) Parasite (11) Prostaglandin Receptor (1) SARS-CoV (1) Sirtuin (3) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (22) Infection (23) Inflammation/Immunology (15) Metabolic Disease (4)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

hDHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
hDHODH-IN-1 is a *human dihydroorotate* dehydrogenase (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory effect .

DHODH-IN-1	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway .

Vidofludimus 4 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

DHODH-IN-24	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-24 (compound 16) is a potent *human dihydroorotate* dehydrogenase (DHODH) inhibitor with an IC₅₀** of 91 nM .

DSM-421	Dihydroorotate Dehydrogenase Parasite	Infection
DSM-421 is an orally active Dihydroorotate dehydrogenase inhibitor. DSM-421 has antiplasmodium activity .

hDHODH-IN-7	DNA/RNA Synthesis Influenza Virus Dihydroorotate Dehydrogenase	Infection
DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a *human dihydroorotate* dehydrogenase** inhibitor. DHODH-IN-9 has antiviral effect with a pMIC₅₀ of 7.4 .

hDHODH-IN-8	Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma .

DHODH-IN-21	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML) .

MEDS433	Lactate Dehydrogenase	Infection
MEDS433 is a potent inhibitor of *human dihydroorotate* dehydrogenase (hDHODH) with an IC₅₀** of 1.2 nM. MEDS433 exerts a potent antiviral activity against RSV-A and RSV-B in the one-digit nanomolar range. MEDS433 induces the expression of antiviral proteins encoded by interferon stimulated genes (ISGs) able to reduce RSV replication .

UCK2 Inhibitor-3	DNA/RNA Synthesis	Infection Cancer
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC₅₀ value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC₅₀s of 56 μM and 16 μM .

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .

BAY-2402234 5+ Cited Publications	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
BAY-2402234 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies.

P1788	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology Cancer
P1788 is a dihydroorotate dehydrogenase (DHODH) inhibitor. P1788 induces DNA damage .

Leflunomide 5+ Cited Publications HWA486; RS-34821; SU101	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

DHODH-IN-16	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.396 nM for human DHODH .

hDHODH-IN-14	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
hDHODH-IN-14 (compound 14) is a *human dihydroorotate* dehydrogenase (hDHODH) inhibitor with an IC₅₀** of 0.469 μM .

DHODH-IN-11	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pK_a of 5.03 .

DHODH-IN-12	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pK_a of 5.07 .

(E/Z)-Ginkgolic acid C17:2	Dihydroorotate Dehydrogenase	Others
(E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly .

hDHODH-IN-3	Influenza Virus Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
hDHODH-IN-3 (compound 21d) is a *human dihydroorotate* dehydrogenase (HsDHODH) inhibitor, inhibits measles virus replication with a pMIC₅₀** value of 8.6 .

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

AG-636	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 17 nM. AG-636 has strong anticancer effects .

DSM502	Dihydroorotate Dehydrogenase Parasite	Infection
DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs .

Leflunomide (Standard)	Dihydroorotate Dehydrogenase Endogenous Metabolite Bacterial	Cancer
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

hDHODH-IN-13	Dihydroorotate Dehydrogenase	Others
hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD .

PfDHODH-IN-1	Parasite Lactate Dehydrogenase DNA/RNA Synthesis	Infection
PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity .

hDHODH-IN-2	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a *human dihydroorotate* dehydrogenase (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory activity .

BRD9185	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection
BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC₅₀ of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

DSM705	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. DSM705 is a potent antimalarial compound .

Olorofim F901318	Fungal	Infection
Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp. .

hDHODH-IN-4	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Influenza Virus	Infection
hDHODH-IN-4 is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor, with a pIC₅₀ of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a pMIC₅₀ of 8.8 .

DHODH-IN-25	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML) .

Brequinar Maximum Cited Publications 17 Publications Verification DUP785; NSC 368390	Dihydroorotate Dehydrogenase SARS-CoV Virus Protease DNA/RNA Synthesis	Infection Inflammation/Immunology Cancer
Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.

DSM265 1 Publications Verification	Dihydroorotate Dehydrogenase Parasite	Infection
DSM265 is a long-duration inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ of 8.9 nM. DSM265 can also inhibit the growth of Pf3D7 parasites with an EC₅₀ of 4.3 nM .

PfDHODH-IN-2	Dihydroorotate Dehydrogenase Parasite	Infection
PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC₅₀ of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria .

hDHODH-IN-11	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC₅₀ value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML) .

DHODH-IN-14	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis .

DHODH-IN-13	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 4.3 μM for rat liver DHODH. DHODH-IN-13 can be used for rheumatoid arthritis .

DHODH-IN-15	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology
DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis .

DHODH-IN-4	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection Inflammation/Immunology
DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC₅₀ values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity .

DHODH-IN-3	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-3 (compound 3) is a potent inhibitor of *Human Dihydroorotate* Dehydrogenases (HsDHODH) with an IC₅₀ value of 261 nM. DHODH-IN-3 binds to the the ubiquinone binding cavities in DHODH with a K_i ^app** of 32 nM. DHODH-IN-3 has the potential for malaria treatment .

ML390	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

DHODH-IN-8	Parasite Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
DHODH-IN-8 (Compound 27) is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC₅₀s of 0.13 μM and 47.4 μM, and K_is of 0.016 μM and 5.6 μM, respectively. DHODH-IN-8 has antimalarial activity .

DSM705 hydrochloride	Dihydroorotate Dehydrogenase Parasite	Infection
DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC₅₀=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .

Cat. No.	Compare	Product Name	Species	Source

HY-P78957

	Dihydroorotate Dehydrogenase Protein, Human (His) dihydroorotate dehydrogenase (quinone), mitochondrial; DHODH; DHOdehase; dihydroorotate oxidase; dihydroorotate Dehydrogenase	Human	E. coli
	Dihydroorotate dehydrogenase is a key enzyme that utilizes quinones as electron acceptors to catalyze the key conversion of dihydroorotate to orotic acid. This enzyme activity is essential for the de novo biosynthesis of UMP (uridine monophosphate), an essential component of nucleotide metabolism. Dihydroorotate Dehydrogenase Protein, Human (His) is the recombinant human-derived Dihydroorotate Dehydrogenase protein, expressed by E. coli , with N-His labeled tag. The total length of Dihydroorotate Dehydrogenase Protein, Human (His) is 365 a.a., with molecular weight of ~41 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0157S1

Orotic acid-13C,15N2 monohydrate

Orotic acid- ¹³C, ¹⁵N₂ (monohydrate) is the ¹³C and ¹⁵N labeled Orotic acid[1]. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[2][3][4].

HY-B0083S

Leflunomide-d4
Leflunomide-d₄ (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks